SCHEMBL4810503

SCHEMBL4810503

NC(=O)c1ccccc1OCc1ccc(Cl)cc1Br

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PARP1 P09874 5/20 0.52
AKR1C1 Q04828 1/20 0.52
PARP2 Q9UGN5 2/20 0.50
FABP3 P05413 1/20 0.49
FABP4 P15090 1/20 0.49
FABP5 Q01469 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.49
RAB9A P51151 2/20 0.47
POLB P06746 1/20 0.47
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6983631 0.83 ALDH1A1 (0.75) ALDH1A1MAPTMEN1KMT2APARP1
SCHEMBL4810509 0.79 APP (0.43) ALDH1A1MAPTFABP3FABP4FABP5
Hydrochloric Acid SCHEMBL4811143 0.78 APP (0.42) ALDH1A1MAPTMEN1KMT2AFABP3
SCHEMBL4812822 0.77 LMNA (0.55) ALDH1A1MAPTMEN1KMT2APARP1
SCHEMBL27702468 0.77 PARP1 (0.65) ALDH1A1MAPTMEN1KMT2APARP1
SCHEMBL20314154 0.75 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AFABP3FABP4
SCHEMBL5839484 0.74 FABP3 (0.78) ALDH1A1MEN1KMT2AFABP3FABP4
SCHEMBL9824901 0.73 FABP3 (0.64) ALDH1A1MAPTMEN1KMT2AFABP3
SCHEMBL14879637 0.73 HTT (0.68) ALDH1A1MAPTMEN1KMT2APARP1
SCHEMBL22748166 0.73 TSHR (0.41) ALDH1A1MAPTMEN1KMT2AFABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2004-06-10 US claimed
EP-1403258-A1 DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE Ajinomoto Co., Inc. (JP) 2004-03-31 EP claimed
US-7320973-B2 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2008-01-22 US disclosed
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2004-06-10 US disclosed
EP-1403258-A1 DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE Ajinomoto Co., Inc. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same CYP3A4, PPARD, CYP4B1 ALDH1A1 276/4885MAPT 1722/4885MEN1 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.